Neuroacanthocytosis

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC

Neuroacanthocytosis
Synonyms	N/A
Pronounce	N/A
Specialty	N/A
Symptoms	Movement disorders, Chorea, Dystonia, Seizures, Cognitive decline
Complications	N/A
Onset	Typically in adulthood
Duration	Chronic
Types	N/A
Causes	Genetic mutations (e.g., VPS13A, KCTD17)
Risks	Family history of neuroacanthocytosis
Diagnosis	Genetic testing, Blood smear
Differential diagnosis	Huntington's disease, Wilson's disease, Parkinson's disease
Prevention	N/A
Treatment	Symptomatic management, Physical therapy, Speech therapy
Medication	N/A
Prognosis	Progressive, variable
Frequency	Rare
Deaths	N/A

A group of rare genetic disorders affecting the nervous system and red blood cells

Neuroacanthocytosis refers to a group of rare genetic disorders characterized by the presence of acanthocytes in the blood and neurological symptoms. These disorders are typically progressive and can affect various systems in the body, particularly the nervous system.

Overview

Neuroacanthocytosis syndromes are a collection of disorders that share common features, including movement disorders, cognitive decline, and psychiatric symptoms. The presence of acanthocytes, which are spiculated red blood cells, is a hallmark of these conditions. The disorders are genetically heterogeneous, meaning they can be caused by mutations in different genes.

Types of Neuroacanthocytosis

There are several types of neuroacanthocytosis, each with distinct genetic causes and clinical features:

Chorea-acanthocytosis

Chorea-acanthocytosis is an autosomal recessive disorder caused by mutations in the VPS13A gene. It is characterized by chorea, which is a type of involuntary movement, as well as cognitive and behavioral changes. Patients may also experience seizures and myopathy.

McLeod syndrome

McLeod syndrome is an X-linked recessive disorder associated with mutations in the XK gene. It is characterized by movement disorders, peripheral neuropathy, and cardiomyopathy. Acanthocytes are present in the blood, and affected individuals may also have elevated levels of creatine kinase.

Pantothenate kinase-associated neurodegeneration

Pantothenate kinase-associated neurodegeneration (PKAN) is caused by mutations in the PANK2 gene. It is characterized by progressive dystonia, parkinsonism, and iron accumulation in the brain. Although acanthocytes may be present, they are not as prominent as in other neuroacanthocytosis syndromes.

Other forms

Other forms of neuroacanthocytosis include Huntington's disease-like 2 and aceruloplasminemia, which have overlapping features with the aforementioned disorders but are caused by different genetic mutations.

Symptoms

The symptoms of neuroacanthocytosis can vary widely depending on the specific disorder but often include:

• Movement disorders such as chorea, dystonia, and parkinsonism
• Cognitive decline and dementia
• Psychiatric symptoms such as depression and psychosis
• Seizures
• Muscle weakness and atrophy

Diagnosis

Diagnosis of neuroacanthocytosis involves a combination of clinical evaluation, blood tests to detect acanthocytes, and genetic testing to identify specific mutations. Magnetic resonance imaging (MRI) of the brain may also be used to assess structural changes.

Treatment

There is currently no cure for neuroacanthocytosis, and treatment is primarily supportive and symptomatic. Management may include:

• Medications to control movement disorders and psychiatric symptoms
• Physical therapy to maintain mobility
• Occupational therapy to assist with daily activities
• Genetic counseling for affected families

Prognosis

The prognosis for individuals with neuroacanthocytosis varies depending on the specific disorder and its severity. These conditions are generally progressive, leading to increasing disability over time.

See also

• Acanthocyte
• Movement disorder
• Genetic disorder
• Neurology